Summary
This filing is an amendment to Vertex Pharmaceuticals' previous 8-K report, primarily to include unaudited pro forma combined financial information following its merger with Aurora Biosciences Corporation, which closed on July 18, 2001. The merger was structured as a stock-for-stock transaction where Aurora shareholders received 0.62 shares of Vertex common stock for each Aurora share, totaling approximately 14.1 million Vertex shares issued. The pro forma financial statements present the combined entity as if the merger occurred at the beginning of the periods presented, using the pooling of interests method. This provides investors with a clearer view of the merged company's potential financial performance and position, combining historical data from both Vertex and Aurora. The filing also details a change in Vertex's accounting principle for recognizing collaborative R&D revenues, moving to the substantive milestone method, which will be reflected retroactively from January 1, 2001, and will impact its September 30, 2001, financial reporting. Key takeaways for investors include the combined revenue streams and operating expenses, indicating a significant increase in revenue generation potential due to Aurora's discovery services and technology, offset by increased R&D and SG&A expenses. The pro forma balance sheet shows a combined entity with substantial assets and liabilities, including a significant amount of convertible subordinated notes. The pro forma statements, while illustrative, offer a forward-looking perspective on the combined company's financial profile post-merger, highlighting the immediate impact of the accounting change on reported revenues and net loss for the first quarter of 2001.
Key Highlights
- 1Vertex Pharmaceuticals completed a merger with Aurora Biosciences Corporation on July 18, 2001, in a stock-for-stock transaction.
- 2Aurora shareholders received approximately 14.1 million shares of Vertex common stock, with an exchange ratio of 0.62 Vertex shares per Aurora share.
- 3Unaudited pro forma combined financial information is presented, reflecting the merger's impact using the pooling of interests method.
- 4The pro forma statements combine historical financial data from both Vertex and Aurora to show the potential combined financial performance.
- 5Vertex is changing its accounting principle for collaborative R&D revenue recognition to the substantive milestone method, effective January 1, 2001.
- 6The pro forma balance sheet as of March 31, 2001, reflects approximately $21.6 million in estimated merger-related expenses.
- 7The change in accounting principle for revenue recognition resulted in increased deferred revenue and a decrease in stockholders' equity on the pro forma balance sheet.